NCT03686969View on ClinicalTrials.gov

Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis

PHASE3TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

August 2, 2018

Primary Completion Date

November 22, 2018

Study Completion Date

November 29, 2018

Conditions

Dermatomyositis

Interventions

DRUG

Octanorm

Octanorm 0.5g/kg/week

OTHER

Placebo

Placebo

Trial Locations (1)

119992

I.M. SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY Rheumatology Department Of, Clinici Of Nephrology, Moscow

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Octapharma

INDUSTRY